Business

Lasa Supergenerics Q3FY21 PAT at 6.56 Crores up by 154% YoY Finance Cost Reduced by 95.40% YoY

Editor Desk
By Editor Desk

Lasa Supergenerics Limited, a vertically integrated group spanning the entire animal and human healthcare value chain has announced its financial results for the third quarter ended December 31st 2020 (Q3FY21).

Q3FY21 performance overview compared with Q3FY20

  • The Finance cost reduced by 95.40% Y-o-Y from Rs. 1.6 crore in Q3FY20 to Rs. 0.07 crore in Q3FY21

  • Revenues from operations stood at Rs. 53.98 crore as against Rs. 39.29 crore in Q3FY20

  • EBITDA of Rs. 12.56 crore as compared to Rs. 8.16 crore in Q3FY20

  • EBITDA margins at 23.26% as against 20.78% in Q3FY20

  • PAT stood at Rs. 6.56 crore as against of Rs. 2.58 crore

  • EPS for Q3FY21 stood at Rs. 1.61 as compared to Rs. 0.89 in Q3FY20

Q3FY21 performance overview compared with Q2FY21

  • The Finance cost reduced by 60% Q-o-Q from Rs. 0.19 crore in Q2FY21 to Rs. 0.07 crore in Q3FY21

  • Revenues from operations stood at Rs. 53.98 crore as against Rs. 54.69 crore in Q2FY21

  • EBITDA of Rs. 12.56 crore as compared to Rs. 12.79 crore in Q2FY21

  • EBITDA margins at 23.26%

  • PAT stood at Rs. 6.56 crore as compared to Rs. 7.05 crore in Q2FY21

  • EPS for Q3FY21 stood at Rs. 1.61

Highlights For Third quarter ended December 31st 2020

Revenues from operations for the Third quarter ended December 31st, 2020 (Q3FY21) stood at Rs. 53.98 crore.

The Company reported Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) of Rs. 12.56 crore in Q3FY21, as against Rs. 12.79 crore in Q3FY21;